Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 14, 2001

View Archived Issues

INOmax approved in Europe for treating critically ill newborns

Neuroprotective activity of estrogens and SERMs examined at congress

Enrollment begins in new clinical trials of 7-day combination contraceptive patch

Bristol-Myers Squibb selects potential drug targets from Lexicon's LexVision database

Periostat tablets for periodontitis granted dental practitioners formulary status in the UK

Enrollment completed in novel trial for prevention of hypertension

Clinical program for Vitrix living dermal replacement begins

Product R enhances production and secretion of proinflammatory chemokines in human monocytes

Rituximab tested as a treatment for chronic ITP

Pfizer describes erythromycin A derivatives with antibacterial and antiprotozoal activity

New benzamidine derivatives with anticoagulant activity designed by Ajinomoto

Ajinomoto patents new series of factor VII inhibitors

New class of antibacterials reported by Ortho-McNeil

Venlafaxine ER shows good long-term results in GAD patients

First clinical trial of rhuCD40L in cancer patients completed

Approval of Remodulin recommended by the FDA for pulmonary arterial hypertension

FDA approves Natrecor for treatment of congestive heart failure

Zeltia and Ortho Biotech announce licensing agreement for ET-743

New antiarrhythmic agents identified at BMS

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 8, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...